{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:57:54Z","timestamp":1770065874188,"version":"3.49.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background\/Aims<\/jats:title>\n                  <jats:p>Filgotinib (FIL), a Janus kinase inhibitor, shows clinical efficacy in moderate to severe ulcerative colitis (UC), but no prospective studies have examined endoscopic and histopathological outcomes. This study aimed to evaluate the therapeutic efficacy of FIL in moderate to severe UC using the Partial Mayo Score (PMS), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and Geboes Histopathology Score (GHS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-two patients with clinically moderate to severe refractory UC were enrolled. Remission was defined as PMS 0, UCEIS 0, and GHS\u2005&amp;lt;\u20052.0 (sigmoid and rectum). Achievement rates were prospectively evaluated at 12, 24, and 52 weeks after FIL initiation compared to baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 22 patients, comprising Biologic-Na\u00efve (BN, n\u2005=\u200512) and Biologic-Experienced (BE, n\u2005=\u200510) cohorts, achievement rates were highest for PMS 0, followed by UCEIS 0, and lowest for GHS\u2005&amp;lt;\u20052.0. Partial Mayo Score 0 achievement for BN\/BE was 75% (P\u2005=\u2005.001)\/50% (P\u2005=\u2005.031) at 12 weeks, 75% (P\u2005=\u2005.003)\/70% (P\u2005=\u2005.016) at 24 weeks, and 75% (P\u2005=\u2005.002)\/70% (P\u2005=\u2005.016) at 52 weeks. Ulcerative Colitis Endoscopic Index of Severity 0 achievement for BN\/BE was 58.3% (P\u2005=\u2005.008)\/20% (P\u2005=\u2005.016) at 12 weeks, 41.6% (P\u2005=\u2005.019)\/40% (P\u2005=\u2005.016) at 24 weeks, and 50% (P\u2005=\u2005.002)\/50% (P\u2005=\u2005.016) at 52 weeks. Geboes Histopathology Score\u2005&amp;lt;\u20052.0 (sigmoid) achievement for BN\/BE was 25%\/0% at 12 weeks, 33.3%\/10% at 24 weeks, and 25%\/10% at 52 weeks. Geboes Histopathology Score\u2005&amp;lt;\u20052.0 (rectum) achievement for BN\/BE was 50%\/0% at 12 weeks, 41.6%\/20% at 24 weeks, and 33.3%\/40% at 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Filgotinib appears to be an effective treatment for UC, demonstrating potential for achieving not only clinical remission but also endoscopic and histopathological remission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf030","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:09:40Z","timestamp":1744693780000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology Score"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9588-0867","authenticated-orcid":false,"given":"Yoshiyuki","family":"Shirouzu","sequence":"first","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3535-2906","authenticated-orcid":false,"given":"Hideki","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0738-5237","authenticated-orcid":false,"given":"Masayoshi","family":"Kage","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Medicine, Kurume University School of Medicine , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-1486","authenticated-orcid":false,"given":"Yutaro","family":"Mihara","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Medicine, Kurume University School of Medicine , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-8781","authenticated-orcid":false,"given":"Yuka","family":"Sakakibara","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6242-172X","authenticated-orcid":false,"given":"Kazuyoshi","family":"Nagata","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9372-0264","authenticated-orcid":false,"given":"Asami","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5907-7749","authenticated-orcid":false,"given":"Toshihiro","family":"Ohmiya","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8430-9620","authenticated-orcid":false,"given":"Tomoko","family":"Irie","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7897-2915","authenticated-orcid":false,"given":"Yasumi","family":"Araki","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5959-9607","authenticated-orcid":false,"given":"Keiichi","family":"Mitsuyama","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-0129","authenticated-orcid":false,"given":"Hidetoshi","family":"Takedatsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5154-6294","authenticated-orcid":false,"given":"Toshihiro","family":"Noake","sequence":"additional","affiliation":[{"name":"Kurume Coloproctology Center\/Kurume Hospital , Kurume-City ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"12","key":"2025052712331881600_CIT0001","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","article-title":"Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey","volume":"54","author":"Murakami","year":"2019","journal-title":"J Gastroenterol."},{"issue":"2","key":"2025052712331881600_CIT0002","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/01.MIB.0000225339.91484.fc","article-title":"Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study)","volume":"12","author":"Henriksen","year":"2006","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025052712331881600_CIT0003","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"4","key":"2025052712331881600_CIT0004","doi-asserted-by":"publisher","first-page":"371","DOI":"10.19020\/INT.0000000222","article-title":"Considering diagnostic criteria for histological mucosal healing","volume":"22","author":"Ota","year":"2018","journal-title":"Intestine"},{"issue":"5","key":"2025052712331881600_CIT0005","doi-asserted-by":"publisher","first-page":"e000373","DOI":"10.1136\/bmjgast-2020-000373","article-title":"Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation","volume":"7","author":"Alhmoud","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"issue":"6","key":"2025052712331881600_CIT0006","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter","volume":"68","author":"Danese","year":"2019","journal-title":"Gut."},{"issue":"7","key":"2025052712331881600_CIT0007","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov."},{"issue":"8","key":"2025052712331881600_CIT0008","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"2025052712331881600_CIT0009","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/apt.17961","article-title":"Efficacy and safety of filgotinib for ulcerative colitis: a real-world multicenter retrospective study in Japan","volume":"59","author":"Akiyama","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2025052712331881600_CIT0010","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med."},{"issue":"11","key":"2025052712331881600_CIT0011","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)","volume":"61","author":"Travis","year":"2012","journal-title":"Gut."},{"issue":"12","key":"2025052712331881600_CIT0012","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut."},{"issue":"13","key":"2025052712331881600_CIT0013","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/ajg.2012.301","article-title":"Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing","volume":"107","author":"Bessissow","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"14","key":"2025052712331881600_CIT0014","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3390\/ijms24032696","article-title":"CD4 T-Cell subsets and the pathophysiology of inflammatory bowel disease","volume":"24","author":"Gomez-Bris","year":"2023","journal-title":"Int J Mol Sci ."},{"issue":"15","key":"2025052712331881600_CIT0015","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5009\/gnl19334","article-title":"Deep Neural Network-Based Prediction of the Risk of Advanced Colorectal Neoplasia","volume":"15","author":"Min","year":"2021","journal-title":"Gut Liver"},{"issue":"16","key":"2025052712331881600_CIT0016","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/ecco-jcc\/jjw154","article-title":"A simplified geboes score for ulcerative colitis","volume":"11","author":"Jauregui-Amezaga","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"17","key":"2025052712331881600_CIT0017","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","article-title":"Development and validation of a histological index for UC","volume":"66","author":"Mosli","year":"2017","journal-title":"Gut."},{"issue":"18","key":"2025052712331881600_CIT0018","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonization of the approach to ulcerative colitis histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"19","key":"2025052712331881600_CIT0019","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2177\/jsci.33.262","article-title":"Helper T cell paradigm: Th17 and regulatory T cells involved in autoimmune inflammatory disorders, pathogen defense and allergic diseases","volume":"33","author":"Noma","year":"2010","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi."},{"key":"2025052712331881600_CIT0020","first-page":"118","article-title":"The optimal solution for IBD treatment drug prescription derived from patient background and cytokine profile","volume-title":"IBD Treatment","author":"Sugimoto","year":"2023"},{"issue":"22","key":"2025052712331881600_CIT0021","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"issue":"23","key":"2025052712331881600_CIT0022","doi-asserted-by":"publisher","first-page":"jjad187","DOI":"10.1093\/ecco-jcc\/jjad187","article-title":"Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis","volume":"19","author":"Gros","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"23","key":"2025052712331881600_CIT0023","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.cgh.2019.12.011","article-title":"Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis","volume":"18","author":"Pai","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"24","key":"2025052712331881600_CIT0024","doi-asserted-by":"publisher","first-page":"O420","DOI":"10.1111\/codi.12725","article-title":"Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy","volume":"16","author":"Zezos","year":"2014","journal-title":"Colorectal Dis."},{"issue":"25","key":"2025052712331881600_CIT0025","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ecco-jcc\/jjac024","article-title":"The clinical significance of eosinophils in ulcerative colitis: a systematic review","volume":"16","author":"Mookhoek","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"26","key":"2025052712331881600_CIT0026","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/ncomms3675","article-title":"Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation","volume":"4","author":"Kabata","year":"2013","journal-title":"Nat Commun."},{"issue":"27","key":"2025052712331881600_CIT0027","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jgh3.12017","article-title":"Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis","volume":"1","author":"Uchihara","year":"2017","journal-title":"JGH Open"},{"issue":"28","key":"2025052712331881600_CIT0028","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am J Gastroenterol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf030\/62927924\/otaf030.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf030\/62927924\/otaf030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf030\/62927924\/otaf030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:33:22Z","timestamp":1748363602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf030\/8113354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf030","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"otaf030"}}